SNGX SOLIGENIX, INC.

Price Chart

Executive Summary

Soligenix filed a 424B5 prospectus supplement to update the maximum dollar amount of common stock it can sell under its existing at-the-market (ATM) sales agreement with Rodman & Renshaw. The company may now offer and sell up to $2,956,000 in additional common stock, subject to the one-third public float limitation under General Instruction I.B.6 of Form S-3. The stock closed at $0.87 per share on May 27, 2026, representing a significant discount to the $1.42 reference price used to calculate the public float.

Actionable Insight

Key Facts

• Soligenix may sell up to $2,956,000 in additional common stock under its ATM agreement with Rodman & Renshaw.
• The public float is $24,511,625 based on 17,261,708 non-affiliate shares at $1.42 per share (April 27, 2026).
• The stock closed at $0.87 per share on May 27, 2026, a 39% decline from the $1.42 reference price.
• The company has already sold $5,214,498 in securities under General Instruction I.B.6 in the prior 12 months.
• The offering is limited to one-third of the public float in any 12-month period under General Instruction I.B.6.
• Soligenix is a smaller reporting company with a market cap of approximately $13 million.

Financial Impact

Up to $2,956,000 in potential dilution at current market prices, representing approximately 22.7% of the current market cap of $13 million.

Risk Factors

• Significant dilution to existing shareholders if shares are sold at current depressed prices.
• The company may need to raise additional capital beyond this ATM, further pressuring the stock.
• Low stock price and small market cap increase volatility and risk of delisting from Nasdaq.
• The company has already sold $5.2 million under the shelf in the prior 12 months, indicating persistent cash needs.

Market Snapshot

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

US Market Status